The short version of PPARδ agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Cardarine is a common name for GW501516, also GW-1516, a synthetic compound developed as a peroxisome proliferator-activated receptor delta (PPARδ) agonist. It belongs to a class of agents that modulate gene transcription related to lipid and energy metabolism. The compound was studied in preclinical and early clinical research for metabolic and cardiovascular conditions, but it did not progress to approved therapeutic use. Its name appears in fitness and sports contexts despite not being approved as a drug.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
| Property | Value | Notes |
|---|---|---|
| Chemical class | PPARδ agonist | Not an anabolic steroid. |
| Common synonyms | GW501516, GW-1516 | Cardarine is an informal name. |
| Appearance | White to off-white powder | Typical for research-grade solid. |
| Solubility class | Poorly soluble in water; soluble in some organic solvents | Such as DMSO or ethanol in laboratory settings. |
| Typical storage temperature | Cool, dry, protected from light | Specific conditions vary by supplier and form. |
SOCPAC and Southern Command pushed for a significant expansion of American assistance to the Filipino Counterterrorist effort, but being that Sulu was predominantly inhabited by Muslims and was the site where Islam was introduced to the Philippines, many members of both the Philippine and US governments believed that introducing American forces onto Sulu would have been met with intense resistance. Based on a PACOM assessment recommending such a deployment, the Secretary of Defense approved a second iteration of OEF-P to combat terrorism in the Southern Command Area of Responsibility, specifically on Sulu. SOCPAC established a larger JSOTF in Zamboanga and deployed aforce package to the island of Sulu, conducting operations based on the Basilan model. Using that template, SOCPAC deployed one ODB, 5 ODAs to Sulu to advise and assist AFP units in their effort to capture key terrorists. From October 2005 to July 2006, JSOTF-P units assisted Task Force (TF) Comet-the AFP command on Sulu-in setting conditions to deny terrorist sanctuary. ODAs advised their partner army and marine infantry battalions en route and area security to facilitate Filipino sponsored medical, veterinary, and engineer civilian action programs, along with various population engagement activities. These combined efforts succeeded in separating the terrorists from the population. On 27 October 2007, a U.S. Special Forces soldier from 2nd Battalion, 1st SFG was killed in an accidental drowning incident at Lake Seit in the southern Philippines. On 29 September 2009, a roadside bomb killed two U.S.
Prior to 1999, the Engineer designations were 12 series and 83 series. In 1999, CMF 83 changed to CMF 51. In 2004, CMF 51 changed to CMF 21. In 2004, the engineer designation changed from 12 to 21. In 2009, the engineer designation was changed again, from CMF 21 to CMF 12. In 2013, the engineer officer designations 12B (Combat Engineer) and 12D (Facilities/Contract Construction Management Engineer (FCCME)) were consolidated into 12A.
Pathways are required for the maintenance of homeostasis within an organism and the flux of metabolites through a pathway is regulated depending on the needs of the cell and the availability of the substrate. The end product of a pathway may be used immediately, initiate another metabolic pathway or be stored for later use. The metabolism of a cell consists of an elaborate network of interconnected pathways that enable the synthesis and breakdown of molecules (anabolism and catabolism).
Sources: en.wikipedia.org
== Pathophysiology == Coronary occlusion is caused by plaque inside of the blood vessels that direct oxygen rich blood to the heart. Plaque is caused by fatty deposits and scar tissue that cling to the walls of coronary arteries. The development of plaque takes years and leads to stenosis of the coronary arteries and progressively reduces blood flow. Due to the slower development of this condition, the body will adapt and create small blood vessels that circumvent the blockage. The small blood vessels form a natural bypass of the blockage, but often do not supply enough blood to meet an increased demand when stressors are applied like exercise. When a plaque has a greater than 50% diameter stenosis, the reduced blood flow through the coronary artery during exertion may lead to angina. Acute coronary events occur when a thrombus forms due to disruption of a plaque. In acute heart attack, occlusion is greater than in unstable angina, where arterial occlusion is not full blockage. Downstream embolism of thrombus may also produce microinfarcts.
==== Reoxygenation of tolerant animals ==== Hypoxia/anoxia tolerant species handle ROS production during reoxygenation better than the intolerant. In the cortex of the naked mole rats, they show better homeostasis of ROS production than intolerant species and seem to lack the burst of ROS that typically comes with reoxygenation.
=== May === 1 May – MSPs vote 70–58 to defeat a motion of no confidence in the Scottish Government. 2 May – John Swinney is set to become the next SNP leader and first minister after Kate Forbes confirms she will not seek the party's leadership. 5 May – John Swinney warns that any bid to challenge his election as leader would delay rebuilding the party amid reports party activist Graeme McCormick is set to put his name forward. He subsequently announces he will not launch a challenge and endorses Swinney. 6 May – John Swinney is confirmed as Leader of the Scottish National Party after being unopposed in the leadership election, and begins his second tenure in the post. 7 May – John Swinney wins the backing of the Scottish Parliament to become Scotland's seventh First Minister, and will be sworn into office the next day. 8 May – John Swinney is sworn in as Scotland's seventh first minister at a ceremony at the Court of Session in Edinburgh. Swinney appoints Kate Forbes as Scotland's Deputy First Minister. Plans to redevelop Glasgow's Met Tower as a digital technology hub are cancelled, with the company behind the redevelopment citing "significant changes" to economic conditions and the construction market. 9 May – Swinney confirms to the BBC that the SNP's strategy of using the next general election as a mandate for a second referendum on Scottish independence remains. 10 May – Food Standards Scotland confirms a case of BSE has been found on a farm in Ayrshire, but says there is no risk to the public as the animal did not enter the food chain.
Sources: en.wikipedia.org
Cardarine is commonly known as GW501516 or GW-1516. These names refer to the same synthetic compound. It is not a brand-name approved medicine.
No, cardarine is not a steroid. It is classified as a PPARδ agonist. Its structure and receptor target differ from anabolic steroids.
No regulatory agency has approved cardarine as a medicine. It was investigated in early research but development was discontinued. It is not available as a prescription drug.
Cardarine is a common name for GW501516, a synthetic PPARδ agonist developed for research. It has not been approved as a medication in any country. It is classified as an unapproved drug and a prohibited substance in sport.